Compare BGMS & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGMS | BRTX |
|---|---|---|
| Founded | 1996 | 1997 |
| Country | Malaysia | United States |
| Employees | 19 | N/A |
| Industry | | Managed Health Care |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 6.3M |
| IPO Year | N/A | 2015 |
| Metric | BGMS | BRTX |
|---|---|---|
| Price | $1.06 | $0.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 717.3K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | $80,482.35 | $64.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.16 |
| 52 Week High | $6.70 | $1.89 |
| Indicator | BGMS | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.45 | 57.06 |
| Support Level | $0.89 | $0.20 |
| Resistance Level | $1.12 | $0.43 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 79.15 | 64.20 |
Bio Green Med Solution Inc is engaged in the supply and trading of protective and fire safety equipment. The company distributes products such as fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and safety apparel. It also provides fire safety systems, including sprinkler systems, fire alarm systems, valves, and CO2 systems. The company operates across commercial, industrial, healthcare, and residential sectors, with a focus on distribution and compliance with applicable safety standards.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.